Share Price and Basic Stock Data
Last Updated: February 10, 2026, 9:12 pm
| PEG Ratio | -38.51 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Neogen Chemicals Ltd operates in the specialty chemicals sector, focusing on the production of advanced intermediates and specialty chemicals. The company reported a market capitalization of ₹3,362 Cr, with its stock priced at ₹1,271. For the financial year ending March 2023, Neogen recorded sales of ₹686 Cr, up from ₹575 Cr in the previous year, marking a significant growth trajectory. In the trailing twelve months, sales rose to ₹795 Cr, indicating a robust revenue trend. Quarterly sales figures show fluctuations, with a peak of ₹210.30 Cr in March 2024, but a slight dip to ₹164.47 Cr in December 2023. This inconsistency may reflect seasonal demand variations or market conditions impacting revenue generation. Overall, the sales growth over the years—from ₹74 Cr in March 2014 to ₹686 Cr in March 2023—illustrates Neogen’s expanding market presence and operational capacity in the specialty chemicals domain.
Profitability and Efficiency Metrics
Neogen Chemicals has maintained a steady operating profit margin (OPM), which stood at 16.91% in the most recent financial year. Operating profits rose to ₹112 Cr in March 2023 from ₹87 Cr in March 2022. However, the OPM has shown fluctuations over the quarters, with a peak of 20.21% recorded in March 2025, indicating potential operational efficiencies. The company’s return on equity (ROE) is reported at 7.36%, while the return on capital employed (ROCE) is 10.7%, reflecting moderate efficiency in utilizing shareholder funds and total capital. The interest coverage ratio (ICR) stands at 2.89x, suggesting that the company is adequately able to meet its interest obligations, although it is slightly lower compared to previous years. Overall, Neogen’s profitability metrics indicate a stable financial performance, though the variability in OPM points to the need for improved cost management strategies to enhance margins.
Balance Sheet Strength and Financial Ratios
Neogen Chemicals’ balance sheet reflects a total asset value of ₹1,621 Cr as of March 2025, supported by reserves of ₹803 Cr. The company reported borrowings amounting to ₹776 Cr, leading to a debt-to-equity ratio of 0.71x, which is relatively high but manageable within the sector. The current ratio is reported at 1.36x, indicating that Neogen has sufficient short-term assets to cover its liabilities. The company has demonstrated strong growth in book value per share, which increased to ₹299.24 in March 2025 from ₹193.47 in March 2023. With a price-to-book value (P/BV) ratio of 5.16x, Neogen’s valuation appears elevated compared to typical sector ranges, suggesting that the market has high expectations for future growth. Overall, while Neogen’s balance sheet shows strength in asset management, the elevated P/BV ratio may indicate potential overvaluation concerns.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Neogen Chemicals reveals a diverse ownership structure, with promoters holding 51.22% of the equity as of September 2025, a decline from 60.19% in December 2022. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 5.15% and 25.22% of shares, respectively, indicating a healthy institutional interest. The number of shareholders stands at 45,710, reflecting a broad public engagement. The declining promoter stake may raise questions about long-term commitment; however, the stable DII holdings suggest institutional confidence in the company’s future prospects. The dividend payout ratio has reduced to 5% for March 2025, down from 15% for March 2023, indicating a potential reinvestment strategy aimed at growth rather than returning cash to shareholders. This shift could be interpreted as a strategic move to fund expansion plans, although it may impact investor sentiment in the short term.
Outlook, Risks, and Final Insight
Looking ahead, Neogen Chemicals faces both opportunities and risks. The company’s strong revenue growth and operational metrics suggest a positive trajectory in the specialty chemicals market, driven by increasing demand for advanced materials. However, the fluctuation in quarterly sales and profitability metrics indicates potential vulnerabilities to market conditions or operational challenges. Additionally, the high debt levels relative to equity could pose risks during economic downturns, particularly if interest rates rise. On the upside, Neogen’s commitment to reinvesting profits could enhance long-term growth prospects, provided it successfully navigates the competitive landscape. Overall, while Neogen Chemicals demonstrates significant potential for growth, investors should remain cautious of the inherent risks, especially regarding market volatility and financial leverage. A balanced approach to investment, considering both growth potential and risk factors, will be essential for stakeholders moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 381 Cr. | 41.5 | 65.4/35.0 | 23.7 | 20.5 | 0.96 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 31.0 Cr. | 63.2 | 88.8/52.0 | 14.8 | 89.6 | 1.58 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.5 Cr. | 728 | 899/600 | 16.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,300 Cr. | 72.8 | 111/68.2 | 21.8 | 22.0 | 0.69 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 610 Cr. | 243 | 373/208 | 23.3 | 93.8 | 1.03 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 13,082.72 Cr | 748.00 | 59.13 | 182.97 | 0.45% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148.12 | 186.25 | 203.92 | 170.12 | 168.24 | 164.47 | 210.30 | 176.34 | 193.14 | 200.41 | 203.75 | 184.58 | 206.68 |
| Expenses | 123.87 | 156.11 | 171.33 | 140.67 | 142.00 | 142.55 | 172.31 | 144.52 | 156.65 | 162.76 | 162.58 | 149.90 | 171.73 |
| Operating Profit | 24.25 | 30.14 | 32.59 | 29.45 | 26.24 | 21.92 | 37.99 | 31.82 | 36.49 | 37.65 | 41.17 | 34.68 | 34.95 |
| OPM % | 16.37% | 16.18% | 15.98% | 17.31% | 15.60% | 13.33% | 18.06% | 18.04% | 18.89% | 18.79% | 20.21% | 18.79% | 16.91% |
| Other Income | 0.50 | 1.40 | 1.77 | 1.84 | 1.87 | 1.50 | 2.82 | 2.81 | 2.24 | 2.05 | -10.91 | 3.31 | 4.37 |
| Interest | 6.86 | 6.66 | 9.34 | 10.61 | 10.75 | 10.52 | 9.64 | 9.51 | 12.30 | 13.07 | 16.50 | 14.03 | 20.60 |
| Depreciation | 3.88 | 4.14 | 4.29 | 4.92 | 4.93 | 5.74 | 5.81 | 6.39 | 6.61 | 6.58 | 6.01 | 4.88 | 6.39 |
| Profit before tax | 14.01 | 20.74 | 20.73 | 15.76 | 12.43 | 7.16 | 25.36 | 18.73 | 19.82 | 20.05 | 7.75 | 19.08 | 12.33 |
| Tax % | 29.41% | 29.07% | 30.87% | 27.54% | 26.47% | 68.58% | 24.05% | 25.57% | 25.03% | 28.13% | 33.03% | 25.42% | 24.49% |
| Net Profit | 9.89 | 14.71 | 14.33 | 11.42 | 9.14 | 2.25 | 19.26 | 13.94 | 14.86 | 14.41 | 5.19 | 14.23 | 9.31 |
| EPS in Rs | 3.97 | 5.90 | 5.75 | 4.58 | 3.66 | 0.85 | 7.30 | 5.28 | 5.63 | 5.46 | 1.97 | 5.39 | 3.53 |
Last Updated: December 29, 2025, 8:07 pm
Below is a detailed analysis of the quarterly data for Neogen Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 206.68 Cr.. The value appears strong and on an upward trend. It has increased from 184.58 Cr. (Jun 2025) to 206.68 Cr., marking an increase of 22.10 Cr..
- For Expenses, as of Sep 2025, the value is 171.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 149.90 Cr. (Jun 2025) to 171.73 Cr., marking an increase of 21.83 Cr..
- For Operating Profit, as of Sep 2025, the value is 34.95 Cr.. The value appears strong and on an upward trend. It has increased from 34.68 Cr. (Jun 2025) to 34.95 Cr., marking an increase of 0.27 Cr..
- For OPM %, as of Sep 2025, the value is 16.91%. The value appears to be declining and may need further review. It has decreased from 18.79% (Jun 2025) to 16.91%, marking a decrease of 1.88%.
- For Other Income, as of Sep 2025, the value is 4.37 Cr.. The value appears strong and on an upward trend. It has increased from 3.31 Cr. (Jun 2025) to 4.37 Cr., marking an increase of 1.06 Cr..
- For Interest, as of Sep 2025, the value is 20.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.03 Cr. (Jun 2025) to 20.60 Cr., marking an increase of 6.57 Cr..
- For Depreciation, as of Sep 2025, the value is 6.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.88 Cr. (Jun 2025) to 6.39 Cr., marking an increase of 1.51 Cr..
- For Profit before tax, as of Sep 2025, the value is 12.33 Cr.. The value appears to be declining and may need further review. It has decreased from 19.08 Cr. (Jun 2025) to 12.33 Cr., marking a decrease of 6.75 Cr..
- For Tax %, as of Sep 2025, the value is 24.49%. The value appears to be improving (decreasing) as expected. It has decreased from 25.42% (Jun 2025) to 24.49%, marking a decrease of 0.93%.
- For Net Profit, as of Sep 2025, the value is 9.31 Cr.. The value appears to be declining and may need further review. It has decreased from 14.23 Cr. (Jun 2025) to 9.31 Cr., marking a decrease of 4.92 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.53. The value appears to be declining and may need further review. It has decreased from 5.39 (Jun 2025) to 3.53, marking a decrease of 1.86.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74 | 84 | 100 | 110 | 161 | 239 | 306 | 336 | 487 | 686 | 701 | 774 | 795 |
| Expenses | 62 | 71 | 86 | 90 | 132 | 196 | 248 | 272 | 401 | 575 | 585 | 627 | 647 |
| Operating Profit | 11 | 13 | 14 | 20 | 29 | 43 | 58 | 64 | 87 | 112 | 116 | 147 | 148 |
| OPM % | 16% | 15% | 14% | 18% | 18% | 18% | 19% | 19% | 18% | 16% | 17% | 19% | 19% |
| Other Income | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 8 | -4 | -1 |
| Interest | 5 | 5 | 5 | 8 | 10 | 12 | 12 | 14 | 19 | 29 | 42 | 51 | 64 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 12 | 16 | 23 | 26 | 24 |
| Profit before tax | 6 | 8 | 8 | 12 | 18 | 29 | 41 | 44 | 57 | 71 | 59 | 66 | 59 |
| Tax % | 41% | 37% | 39% | 33% | 39% | 28% | 30% | 29% | 22% | 30% | 31% | 27% | |
| Net Profit | 4 | 5 | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 41 | 48 | 43 |
| EPS in Rs | 8.09 | 11.31 | 2.59 | 3.88 | 5.34 | 10.48 | 12.33 | 13.47 | 17.93 | 20.07 | 15.59 | 18.35 | 16.35 |
| Dividend Payout % | 25% | 18% | 77% | 26% | 19% | 14% | 16% | 17% | 15% | 15% | 13% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 0.00% | 60.00% | 37.50% | 90.91% | 38.10% | 6.90% | 45.16% | 11.11% | -18.00% | 17.07% |
| Change in YoY Net Profit Growth (%) | 0.00% | -25.00% | 60.00% | -22.50% | 53.41% | -52.81% | -31.20% | 38.26% | -34.05% | -29.11% | 35.07% |
Neogen Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 15% |
| 3 Years: | 9% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | -1% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:43 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 20 | 20 | 20 | 20 | 23 | 23 | 25 | 25 | 26 | 26 | 26 |
| Reserves | 15 | 19 | 8 | 22 | 31 | 50 | 133 | 160 | 414 | 458 | 740 | 782 | 803 |
| Borrowings | 25 | 24 | 26 | 69 | 82 | 120 | 137 | 222 | 229 | 370 | 409 | 474 | 776 |
| Other Liabilities | 18 | 21 | 27 | 41 | 48 | 56 | 61 | 87 | 131 | 202 | 230 | 338 | 344 |
| Total Liabilities | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 | 1,949 |
| Fixed Assets | 14 | 13 | 17 | 56 | 67 | 83 | 111 | 127 | 285 | 347 | 361 | 228 | 251 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 115 | 11 | 36 | 56 | 28 | 54 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 77 | 5 | 193 | 400 |
| Other Assets | 49 | 55 | 62 | 94 | 112 | 163 | 242 | 250 | 423 | 594 | 983 | 1,173 | 1,244 |
| Total Assets | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 | 1,949 |
Below is a detailed analysis of the balance sheet data for Neogen Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
- For Reserves, as of Sep 2025, the value is 803.00 Cr.. The value appears strong and on an upward trend. It has increased from 782.00 Cr. (Mar 2025) to 803.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 776.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 474.00 Cr. (Mar 2025) to 776.00 Cr., marking an increase of 302.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 344.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 338.00 Cr. (Mar 2025) to 344.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,949.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,621.00 Cr. (Mar 2025) to 1,949.00 Cr., marking an increase of 328.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 228.00 Cr. (Mar 2025) to 251.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2025) to 54.00 Cr., marking an increase of 26.00 Cr..
- For Investments, as of Sep 2025, the value is 400.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 400.00 Cr., marking an increase of 207.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,244.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,173.00 Cr. (Mar 2025) to 1,244.00 Cr., marking an increase of 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,949.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,621.00 Cr. (Mar 2025) to 1,949.00 Cr., marking an increase of 328.00 Cr..
Notably, the Reserves (803.00 Cr.) exceed the Borrowings (776.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.00 | -11.00 | -12.00 | -49.00 | -53.00 | -77.00 | -79.00 | -158.00 | -142.00 | -258.00 | -293.00 | -327.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 78 | 58 | 107 | 94 | 93 | 90 | 85 | 82 | 94 | 147 | 94 |
| Inventory Days | 173 | 178 | 190 | 228 | 192 | 188 | 257 | 211 | 258 | 275 | 353 | 265 |
| Days Payable | 117 | 120 | 130 | 177 | 141 | 111 | 71 | 122 | 131 | 147 | 134 | 220 |
| Cash Conversion Cycle | 138 | 136 | 117 | 158 | 145 | 169 | 276 | 174 | 209 | 223 | 366 | 138 |
| Working Capital Days | 140 | 140 | 126 | 67 | 49 | 63 | 96 | 67 | 111 | 80 | 190 | 169 |
| ROCE % | 26% | 27% | 26% | 23% | 23% | 26% | 22% | 17% | 14% | 13% | 10% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 1,248,272 | 0.3 | 147.82 | 808,141 | 2025-12-07 15:45:16 | 54.46% |
| Axis Small Cap Fund | 1,217,809 | 0.54 | 144.21 | 1,217,809 | 2025-04-22 17:25:25 | 0% |
| SBI Large & Midcap Fund | 935,051 | 0.3 | 110.73 | 935,051 | 2025-04-22 15:56:55 | 0% |
| Sundaram Small Cap Fund | 317,000 | 1.1 | 37.54 | 271,539 | 2026-01-25 00:00:00 | 16.74% |
| Invesco India Smallcap Fund | 222,523 | 0.29 | 26.35 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 212,801 | 0.19 | 25.2 | 212,801 | 2025-04-22 15:56:55 | 0% |
| WhiteOak Capital Flexi Cap Fund | 152,949 | 0.26 | 18.11 | N/A | N/A | N/A |
| SBI Comma Fund | 152,080 | 2.09 | 18.01 | N/A | N/A | N/A |
| Axis Innovation Fund | 118,806 | 1.18 | 14.07 | N/A | N/A | N/A |
| Mirae Asset Healthcare Fund | 102,961 | 0.44 | 12.19 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Diluted EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Cash EPS (Rs.) | 23.66 | 22.11 | 26.49 | 22.58 | 16.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Revenue From Operations / Share (Rs.) | 294.75 | 261.82 | 275.13 | 195.37 | 144.17 |
| PBDIT / Share (Rs.) | 53.20 | 44.55 | 46.54 | 35.22 | 27.81 |
| PBIT / Share (Rs.) | 42.66 | 35.88 | 40.04 | 30.53 | 24.85 |
| PBT / Share (Rs.) | 18.94 | 19.93 | 28.44 | 22.88 | 18.95 |
| Net Profit / Share (Rs.) | 13.13 | 13.45 | 20.00 | 17.89 | 13.43 |
| NP After MI And SOA / Share (Rs.) | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 |
| PBDIT Margin (%) | 18.04 | 17.01 | 16.91 | 18.02 | 19.28 |
| PBIT Margin (%) | 14.47 | 13.70 | 14.55 | 15.62 | 17.23 |
| PBT Margin (%) | 6.42 | 7.61 | 10.33 | 11.71 | 13.14 |
| Net Profit Margin (%) | 4.45 | 5.13 | 7.26 | 9.15 | 9.31 |
| NP After MI And SOA Margin (%) | 4.47 | 5.16 | 7.28 | 9.15 | 9.31 |
| Return on Networth / Equity (%) | 4.41 | 4.68 | 10.35 | 10.16 | 17.11 |
| Return on Capital Employeed (%) | 11.09 | 10.12 | 15.50 | 13.10 | 18.23 |
| Return On Assets (%) | 1.99 | 2.43 | 4.74 | 5.58 | 6.36 |
| Long Term Debt / Equity (X) | 0.21 | 0.16 | 0.26 | 0.27 | 0.63 |
| Total Debt / Equity (X) | 0.71 | 0.51 | 0.75 | 0.45 | 1.10 |
| Asset Turnover Ratio (%) | 0.48 | 0.54 | 0.74 | 0.75 | 0.79 |
| Current Ratio (X) | 1.36 | 1.49 | 1.60 | 2.26 | 1.38 |
| Quick Ratio (X) | 0.94 | 0.76 | 0.88 | 1.37 | 0.72 |
| Inventory Turnover Ratio (X) | 2.25 | 1.41 | 1.99 | 2.23 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 15.15 | 20.98 | 13.72 | 11.76 | 14.89 |
| Dividend Payout Ratio (CP) (%) | 8.43 | 12.78 | 10.36 | 9.32 | 12.20 |
| Earning Retention Ratio (%) | 84.85 | 79.02 | 86.28 | 88.24 | 85.11 |
| Cash Earning Retention Ratio (%) | 91.57 | 87.22 | 89.64 | 90.68 | 87.80 |
| Interest Coverage Ratio (X) | 2.89 | 2.79 | 4.01 | 4.60 | 4.71 |
| Interest Coverage Ratio (Post Tax) (X) | 2.00 | 1.84 | 2.72 | 3.34 | 3.28 |
| Enterprise Value (Cr.) | 4637.05 | 3527.65 | 3541.31 | 4504.16 | 2217.48 |
| EV / Net Operating Revenue (X) | 5.96 | 5.11 | 5.16 | 9.24 | 6.59 |
| EV / EBITDA (X) | 33.04 | 30.02 | 30.51 | 51.28 | 34.18 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 5.99 |
| Retention Ratios (%) | 84.84 | 79.01 | 86.27 | 88.23 | 85.10 |
| Price / BV (X) | 5.16 | 4.14 | 6.63 | 9.91 | 11.02 |
| Price / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 6.00 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Neogen Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.66. This value is within the healthy range. It has increased from 22.11 (Mar 24) to 23.66, marking an increase of 1.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.75. It has increased from 261.82 (Mar 24) to 294.75, marking an increase of 32.93.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.20. This value is within the healthy range. It has increased from 44.55 (Mar 24) to 53.20, marking an increase of 8.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.66. This value is within the healthy range. It has increased from 35.88 (Mar 24) to 42.66, marking an increase of 6.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has decreased from 19.93 (Mar 24) to 18.94, marking a decrease of 0.99.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 13.45 (Mar 24) to 13.13, marking a decrease of 0.32.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.51 (Mar 24) to 13.20, marking a decrease of 0.31.
- For PBDIT Margin (%), as of Mar 25, the value is 18.04. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 18.04, marking an increase of 1.03.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 13.70 (Mar 24) to 14.47, marking an increase of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 7.61 (Mar 24) to 6.42, marking a decrease of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 4.45. This value is below the healthy minimum of 5. It has decreased from 5.13 (Mar 24) to 4.45, marking a decrease of 0.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.47. This value is below the healthy minimum of 8. It has decreased from 5.16 (Mar 24) to 4.47, marking a decrease of 0.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 15. It has decreased from 4.68 (Mar 24) to 4.41, marking a decrease of 0.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 11.09, marking an increase of 0.97.
- For Return On Assets (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 5. It has decreased from 2.43 (Mar 24) to 1.99, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.21, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.71, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.48. It has decreased from 0.54 (Mar 24) to 0.48, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 1.5. It has decreased from 1.49 (Mar 24) to 1.36, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.25. This value is below the healthy minimum of 4. It has increased from 1.41 (Mar 24) to 2.25, marking an increase of 0.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.15. This value is below the healthy minimum of 20. It has decreased from 20.98 (Mar 24) to 15.15, marking a decrease of 5.83.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.43. This value is below the healthy minimum of 20. It has decreased from 12.78 (Mar 24) to 8.43, marking a decrease of 4.35.
- For Earning Retention Ratio (%), as of Mar 25, the value is 84.85. This value exceeds the healthy maximum of 70. It has increased from 79.02 (Mar 24) to 84.85, marking an increase of 5.83.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.57. This value exceeds the healthy maximum of 70. It has increased from 87.22 (Mar 24) to 91.57, marking an increase of 4.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 3. It has increased from 2.79 (Mar 24) to 2.89, marking an increase of 0.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.00. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.00, marking an increase of 0.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,637.05. It has increased from 3,527.65 (Mar 24) to 4,637.05, marking an increase of 1,109.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 5.11 (Mar 24) to 5.96, marking an increase of 0.85.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 30.02 (Mar 24) to 33.04, marking an increase of 3.02.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For Retention Ratios (%), as of Mar 25, the value is 84.84. This value exceeds the healthy maximum of 70. It has increased from 79.01 (Mar 24) to 84.84, marking an increase of 5.83.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.16, marking an increase of 1.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neogen Chemicals Ltd:
- Net Profit Margin: 4.45%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.09% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.41% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 70.4 (Industry average Stock P/E: 59.13)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.45%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | No. 1002, 10th Floor, Dev Corpora Bldg, Thane Maharashtra 400601 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Haridas Kanani | Chairman & Managing Director |
| Dr. Harin Kanani | Managing Director |
| Mr. Shyamsunder Upadhyay | Whole Time Director |
| Mr. Anurag Surana | Non Exe.Non Ind.Director |
| Mr. Rajeshkumar Shah | Independent Director |
| Mr. Manojkumar Pati | Independent Director |
| Prof. Ranjan Kumar Malik | Independent Director |
| Mrs. Avi Sabavala | Independent Director |
FAQ
What is the intrinsic value of Neogen Chemicals Ltd?
Neogen Chemicals Ltd's intrinsic value (as of 10 February 2026) is ₹1278.81 which is 2.75% lower the current market price of ₹1,315.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,479 Cr. market cap, FY2025-2026 high/low of ₹2,061/967, reserves of ₹803 Cr, and liabilities of ₹1,949 Cr.
What is the Market Cap of Neogen Chemicals Ltd?
The Market Cap of Neogen Chemicals Ltd is 3,479 Cr..
What is the current Stock Price of Neogen Chemicals Ltd as on 10 February 2026?
The current stock price of Neogen Chemicals Ltd as on 10 February 2026 is ₹1,315.
What is the High / Low of Neogen Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neogen Chemicals Ltd stocks is ₹2,061/967.
What is the Stock P/E of Neogen Chemicals Ltd?
The Stock P/E of Neogen Chemicals Ltd is 70.4.
What is the Book Value of Neogen Chemicals Ltd?
The Book Value of Neogen Chemicals Ltd is 314.
What is the Dividend Yield of Neogen Chemicals Ltd?
The Dividend Yield of Neogen Chemicals Ltd is 0.08 %.
What is the ROCE of Neogen Chemicals Ltd?
The ROCE of Neogen Chemicals Ltd is 10.7 %.
What is the ROE of Neogen Chemicals Ltd?
The ROE of Neogen Chemicals Ltd is 7.36 %.
What is the Face Value of Neogen Chemicals Ltd?
The Face Value of Neogen Chemicals Ltd is 10.0.